KNect365 Life Sciences is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Next Generation Therapeutics

The Regulatory Environment of Microbiome-Based Therapies in the US and EU - WHITEPAPER

ArticleImage

Download the exclusive whitepaper

The advancement of live microbiome therapies into later phase clinical trials has raised hopes of a near-future where we will be able to prevent or treat diseases by modulating the microbiome. While new companies are joining the microbiome industry each year, there is one barrier of entry that makes life in the industry as difficult as one can expect in an emerging field: regulatory uncertainty. This whitepaper reviews the current situation in two parts of the world where the microbiome industry is advancing fast, namely the US and the EU.

It looks at two case studies: the uncertain status of fecal microbiota transplantation (FMT) in the US and  FMT under Gene, Cells, and Tissue Regulations in Europe.

To download the exclusive whitepaper simply log in or register for a KNect365 account, which will give you access to all our exclusive premium content.

Have any questions about the report or interested in sponsoring a future whitepaper? Email andrew.burrows@knect365.com.

Create your KNect365 account

Access this and more industry news, views, and keynotes from influencers and market movers.
Show
Please tick these boxes if you do not wish to receive marketing information relevant to you from KNect365 Life Sciences:
By creating an account you agree to Informa's Terms of Use and Privacy Policy